Chong Kun Dang Voluntarily Halts Phase 3 Clinical Trial of 'Nafabaltan' COVID-19 Treatment

[Asia Economy Reporter Lee Jung-yoon] Chong Kun Dang announced on the 1st that it has voluntarily discontinued the Phase 3 clinical trial of Napabeltan injection.

This is a Phase 3 clinical trial to evaluate the efficacy and safety of CKD-314 (Napabeltan injection) in patients diagnosed with COVID-19 pneumonia who were hospitalized.

The company stated, "Due to the decrease in COVID-19 incidence and the reduced progression rate to severe cases as a result of widespread vaccination, there are difficulties in conducting the clinical trial," adding, "Therefore, a change in development strategy is inevitable, and considering the opinions of COVID-19 experts and the overall situation, we have decided to discontinue this clinical trial."